C Michael Gibson Discussing The Results of The Phase III OCEANIC-STROKE Trial with Mike Sharma
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%.
The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.
There was no increase in mild or severe bleeding or intracranial bleeding
63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy
Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin
All benefit with no increase in bleeding risk
View slides here.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Mar 22, 2026, 17:21Arrigo Francesco Giuseppe Cicero: Diagnostic and Prognostic Perspectives of Glycocalyx Disruption in Pregnancy
-
Mar 22, 2026, 17:19Veronica Sanchez: Stress from Pregnancy Complications Impacts The Long-Term Cardiovascular Health
-
Mar 22, 2026, 16:21Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
-
Mar 22, 2026, 16:14Andre W. Bourgoyne: Anemia Management as a Comprehensive Hospital Performance Strategy
-
Mar 22, 2026, 16:03Fibrinogen-Guided Management of Postpartum Hemorrhage – Transfusion Medicine KMC Manipal
-
Mar 22, 2026, 15:48Simon Senanu: Diagnostic Significance of Target Cells in Peripheral Blood Smear
-
Mar 22, 2026, 15:43Hayley Evans: What If The Decision Support System Is Part of The Problem?
-
Mar 22, 2026, 15:29Archit Pandharipande: The Burden and Impact of Heavy Menstrual Bleeding in Adolescents with Bleeding Disorders
-
Mar 22, 2026, 15:17Mamtha Balla: Mastering the Lab and Clinical Connection in Hemostasis and Thrombosis